{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:55:51Z","timestamp":1778349351413,"version":"3.51.4"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The predictive power of serum \u03ba\/\u03bb ratios on initial presentation of immunoglobulin G (IgG) or IgA monoclonal component was studied to differentiate between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients. The retrospective study involved 145 patients clinically diagnosed with monoclonal gammopathy of undetermined significance or multiple myeloma, who had serum M-protein IgG &lt;35g\/L or IgA &lt;20g\/L at M-protein detection. Serum light chains \u03ba and \u03bb were measured by fixed-time nephelometry. Test performance indices, predictive values and likelihood ratios were calculated according to the Weissler recommendation. MM patients were considered as diseased and MGUS patients as non-diseased in order to estimate the performance characteristics of serum \u03ba\/\u03bb ratios. There was a statistically significant difference in \u03ba\/\u03bb ratios distribution between both groups of patients, in both M-protein \u03ba-type (Mann-Whitney U=168, p&lt;0.001) and in M-protein \u03bb-type (Mann-Whitney U=143, p&lt;0.001). Negative likelihood ratios at threshold levels of 0.6 and 4.2 were 2.17- and 3.32-fold greater, respectively, than positive likelihood ratios, so that the predictive power of a serum \u03ba\/\u03bb ratio within these limits is better in ruling out (negative predictive power) than ruling in disease (positive predictive power). The post-test characteristics of a serum \u03ba\/\u03bb ratio interval between 0.6 and 4.2 in discriminating MGUS from MM in our geographic population were: sensitivity 0.96 (0.93\u20130.99 95%CI); specificity 0.70 (0.63\u20130.77); positive predictive value 0.68 (0.64\u20130.73); negative predictive value 0.96 (0.94\u20130.99); likelihood ratios (+)LR 3.23 (2.68\u20134.04); and (\u2212)LR 17.16 (11.00\u201363.00). Thus, serum M-protein with a \u03ba\/\u03bb ratio between 0.6 and 4.2 increases the posterior probability of MGUS from 0.60 to 0.96 in asymptomatic patients, for whom only monitoring may be suggested when the serum \u03ba\/\u03bb ratio is within these limits.<\/jats:p>","DOI":"10.1515\/cclm.2005.004","type":"journal-article","created":{"date-parts":[[2005,1,6]],"date-time":"2005-01-06T17:19:31Z","timestamp":1105031971000},"source":"Crossref","is-referenced-by-count":5,"title":["The predictive power of serum \u03ba\/\u03bb ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma"],"prefix":"10.1515","volume":"43","author":[{"given":"Enrique","family":"Berg\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Miravalles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Berg\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Berg\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref71","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.V87.3.912.bloodjournal873912","article-title":"Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy","volume":"87","author":"Baldini","year":"1996","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/10428190109099321","article-title":"de Malignant transformation of monoclonal gammopathy of undetermined significance : cumulative incidence and prognostic factors","volume":"42","author":"Van","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathies of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref81","first-page":"346","article-title":"A long - term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"9","author":"Kyle","year":"2002","journal-title":"Engl J Med"},{"key":"ref151","first-page":"1172","article-title":"The impact of component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Gregersen","year":"2001","journal-title":"Haematologica"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4065\/74.11.1061","article-title":"A perspective on standardizing the predictive power of non - invasive cardiovascular tests by likelihood ratio computation mathematical principles","volume":"74","author":"Weissler","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"ref41","first-page":"300","article-title":"Staging and kinetics of multiple myeloma","volume":"13","author":"Durie","year":"1986","journal-title":"Sem Oncol"},{"key":"ref51","first-page":"135","article-title":"Frecuencia de gammapat\u00edas monoclonales en una muestra no seleccionada","volume":"16","author":"Berg\u00f3n","year":"1997","journal-title":"Quim Clin"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4065\/74.11.1072","article-title":"A perspective on standardizing the predictive power of non - invasive cardiovascular tests by likelihood ratio computation Clinical applications","volume":"74","author":"Weissler","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0889-8588(05)70416-0","article-title":"Monoclonal gammopathy of undetermined significance and solitary plasmocytoma Implications for progression to overt multiple myeloma","volume":"11","author":"Kyle","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000203676","article-title":"The natural history of monoclonal gammopathy of undetermined significance to - year follow - up of cases","volume":"5","author":"Pasqualetti","year":"1997","journal-title":"Acta Haematol"},{"key":"ref01","first-page":"234","article-title":"Presenting features of monoclonal gammopathies : an analysis of newly diagnosed cases","volume":"684","author":"Ucci","year":"1993","journal-title":"J Intern Med"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2005.43.issue-1\/cclm.2005.004\/cclm.2005.004.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2005.004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T22:44:27Z","timestamp":1619045067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2005.004\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":12,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1515\/cclm.2005.004","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}